Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4,534 Mln
Revenue (TTM)
$634 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
16.5
Industry P/E
--
EV/EBITDA
87
Div. Yield
0 %
Debt to Equity
1.8
Book Value
$0.9
EPS
$-0.1
Face value
--
Shares outstanding
314,000,712
CFO
$-1,739.65 Mln
EBITDA
$-1,894.10 Mln
Net Profit
$-2,305.94 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amicus Therapeutics (FOLD)
| 1.4 | 0.5 | 1.4 | 81.6 | 9.2 | 7.5 | 5.2 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Amicus Therapeutics (FOLD)
| 51.2 | -33.4 | 16.2 | 5.7 | -50.0 | 137.1 | 1.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amicus Therapeutics (FOLD)
|
14.4 | 4,534.2 | 634.2 | -27.1 | 7.3 | -11.6 | -- | 16.5 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 229.3 | 14,074.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of... Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Read more
CEO, President & Director
Mr. Bradley L. Campbell M.B.A.
CEO, President & Director
Mr. Bradley L. Campbell M.B.A.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Amicus Therapeutics Inc (FOLD) is $14.44 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Amicus Therapeutics Inc (FOLD) has given a return of 9.2% in the last 3 years.
Since, TTM earnings of Amicus Therapeutics Inc (FOLD) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-165.12
|
16.32
|
|
2024
|
-50.21
|
14.52
|
|
2023
|
-27.48
|
26.01
|
|
2022
|
-14.51
|
27.89
|
|
2021
|
-12.86
|
10.48
|
The 52-week high and low of Amicus Therapeutics Inc (FOLD) are Rs 14.46 and Rs 5.51 as of 05-Apr-2026.
Amicus Therapeutics Inc (FOLD) has a market capitalisation of $ 4,534 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Amicus Therapeutics Inc (FOLD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.